Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
versavo
- Development stage
- Unknown
- Lead developer
- Dr. Reddy's Laboratories
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Versavo is a biosimilar of bevacizumab, developed and manufactured by Dr. Reddy's Laboratories. Bevacizumab is a humanized recombinant monoclonal antibody that targets and neutralizes vascular endothelial growth factor A (VEGF-A), the principal driver of angiogenesis in tumors. By binding to VEGF-A, Versavo inhibits its interaction with VEGF receptors on endothelial cells, thereby blocking the formation of new blood vessels (angiogenesis) essential for tumor growth and metastasis. Versavo is indicated for use in combination with chemotherapy or other agents for the treatment of multiple cancers including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer (NSCLC), recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, ovarian cancer, metastatic breast cancer, as well as cancers of the fallopian tube or primary peritoneal origin[1][2][3][4][5][6][7][8][9].
- Brand names
- versavopersivia
- Other names
- bevacizumab biosimilar
02
Targets
Beyond the preview
Go deeper on versavo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on versavo.